AbstractHospital acquired infections greatly affect recovery and survival in pediatric surgical patients. We evaluated prevalence and antimicrobial resistance of ESKAPE pathogens in neonates and infants subjected to cardiac surgery in a tertiary hospital in Central Kazakhstan between 2019 and 2023 (2,278 patients) using routine methods of microbiological detection. ESKAPE pathogens were found in 1,899 out of 2,957 samples (Staphylococcus aureus – 35.3%, Klebsiella pneumoniae – 27.8%, Acinetobacter baumannii – 14.5%, Pseudomonas aeruginosa – 12.4%, Enterobacter sp. – 8.8%, Enterococcus faecium – 1.2%). The total prevalence of ESKAPE increased significantly from 45.1 to 76.9% (P = 0.005) during the study period. The resistance significantly increased in methicillin-resistant S. aureus (MRSA, from 13.7 to 41.9%, P = 0.041) but decreased in carbapenem-resistant P. aeruginosa (from 64.3 to 37.7%, P = 0.037) and carbapenem-resistant A. baumannii (from 48.5 to 19.1%, P = 0.039). Gradual but non-significant changes were shown in third-generation cephalosporin resistant K. pneumoniae (from 63.6 to 45.2%) and carbapenem-resistant K. pneumoniae (from 0 to 8.3%). The relative prevalence of ESKAPE pathogens steadily increased in our pediatric cardiac surgery patients in 2019–2023. The most frequent were S. aureus, K. pneumoniae, and A. baumannii, with dramatically increasing tendencies for MRSA. Our results highlight the necessity for a well-designed infection control strategy and constant microbiological monitoring in pediatric cardiac surgery departments.

npj Vaccines

A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens

Article

Author: Sadones, Oceane ; Autiero, Ida ; Berisio, Rita ; Skurnik, David ; Huebner, Johannes ; Squeglia, Flavia ; Romero-Saavedra, Felipe ; Toumi, Eya ; Kramarska, Eliza ; Laverde, Diana ; Napolitano, Valeria ; Frapy, Eric

ESKAPE pathogens are responsible for complicated nosocomial infections worldwide and are often resistant to commonly used antibiotics in clinical settings. Among ESKAPE, vancomycin-resistant Enterococcus faecium (VREfm) and methicillin-resistant Staphylococcus aureus (MRSA) are two important Gram-positive pathogens for which non-antibiotic alternatives are urgently needed. We previously showed that the lipoprotein AdcA of E. faecium elicits opsonic and protective antibodies against E. faecium and E. faecalis. Prompted by our observation, reported here, that AdcA also elicits opsonic antibodies against MRSA and other clinically relevant Gram-positive pathogens, we identified the dominant epitope responsible for AdcA cross-reactive activity and designed a hyper-thermostable and multi-presenting antigen, Sc(EH)₃. We demonstrate that antibodies raised against Sc(EH)₃ mediate opsonic killing of a wide-spectrum of Gram-positive pathogens, including VREfm and MRSA, and confer protection both in passive and active immunisation models. Our data indicate that Sc(EH)₃ is a promising antigen for the development of vaccines against different Gram-positive pathogens.

100 Deals associated with ESKAPE pathogens(ABAC Therapeutics)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acinetobacter Baumannii Infection	Preclinical	ES	ABAC Therapeutics SLStartup	10 Aug 2024
Enterobacter Infection	Preclinical	ES	ABAC Therapeutics SLStartup	10 Aug 2024
Enterococcus faecium infection	Preclinical	ES	ABAC Therapeutics SLStartup	10 Aug 2024
Klebsiella pneumoniae infection	Preclinical	ES	ABAC Therapeutics SLStartup	10 Aug 2024
Pseudomonas aeruginosa infection	Preclinical	ES	ABAC Therapeutics SLStartup	10 Aug 2024
Staphylococcus Aureus Infections	Preclinical	ES	ABAC Therapeutics SLStartup	10 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ESKAPE pathogens(ABAC Therapeutics)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation